Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 14, 2015 - Issue 3
Submit an article Journal homepage
870
Views
17
CrossRef citations to date
0
Altmetric
Review

Systemic safety of anti-VEGF drugs: a commentary

Lauren J ScottUniversity of Bristol, School of Clinical Sciences, Clinical Trials and Evaluation Unit, Level 7, Queen’s Building, Bristol Royal Infirmary, Bristol, BS2 8HW, UK
, BSc MSc (Medical Statistician) ,
Usha ChakravarthyQueen’s University of Belfast, Centre for Experimental Medicine, Dentistry and Biomedical Sciences, University road, Belfast, UK
, MBBS FRCS FRCOphth PhD (Professor of Ophthalmology and Vision Science) ,
Barnaby C ReevesUniversity of Bristol, School of Clinical Sciences, Clinical Trials and Evaluation Unit, Level 7, Queen’s Building, Bristol Royal Infirmary, Bristol, BS2 8HW, UK
, BA DPhil MSc PhD MFPHM (Professorial Research Fellow in Health Services Research) &
Chris A RogersUniversity of Bristol, School of Clinical Sciences, Clinical Trials and Evaluation Unit, Level 7, Queen’s Building, Bristol Royal Infirmary, Bristol, BS2 8HW, UK+44 0117 342 2507; +44 0117 342 3288; [email protected]
, BSc PhD PGCE (Reader in Medical Statistics)
Pages 379-388 | Published online: 09 Dec 2014

Citations (17)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Focke Ziemssen, Bianka Sobolewska, Heidrun Deissler & Helmut Deissler. (2016) Safety of monoclonal antibodies and related therapeutic proteins for the treatment of neovascular macular degeneration: addressing outstanding issues. Expert Opinion on Drug Safety 15:1, pages 75-87.
Read now

Articles from other publishers (16)

Xing Wang & Peng Wang. (2023) Spectral-domain optical coherence tomography combined with electroretinography in the assessment of conbercept for neovascular age-related macular degeneration: a preliminary study. Frontiers in Neuroscience 17.
Crossref
Robert S. Bresalier, Emmanuel S. Coronel & Hao Chi Zhang. 2017. Holland‐Frei Cancer Medicine. Holland‐Frei Cancer Medicine 1 18 .
Panpan Liu, Lihong Qin, Chang Liu, Jun Mi, Qun Zhang, Shuangshuang Wang, Dexuan Zhuang, Qiuping Xu, Wenqian Chen, Jing Guo & Xunwei Wu. (2022) Exosomes Derived From Hypoxia-Conditioned Stem Cells of Human Deciduous Exfoliated Teeth Enhance Angiogenesis via the Transfer of let-7f-5p and miR-210-3p. Frontiers in Cell and Developmental Biology 10.
Crossref
Sirpa Loukovaara & Jari Haukka. (2021) Intravitreal anti‐VEGF therapy is not associated with a higher risk of all‐cause mortality in patients with macular oedema caused by posterior segment vascular diseases. Acta Ophthalmologica 99:6.
Crossref
Hiroki Tanaka, Yu Sakurai, Jessica Anindita & Hidetaka Akita. (2020) Development of lipid-like materials for RNA delivery based on intracellular environment-responsive membrane destabilization and spontaneous collapse. Advanced Drug Delivery Reviews 154-155, pages 210-226.
Crossref
Cheng LiXiaoxiao FengXin WenYujie LiBingqian LiuJie HuLin LuYehong ZhuoYue FuXiaobing QianWanwen ShaoQishan ZhengLeilei LinYao YangHaihua ZhengXiaofeng LinQianying Gao. (2019) A Pilot Clinical Study of Intravitreal Injection of Artesunate for Ocular Neovascularization. Journal of Ocular Pharmacology and Therapeutics 35:5, pages 283-290.
Crossref
Michel M. Sun, Ann M. Chan, Samuel M. Law, Sergio Duarte, Daniel Diaz-Aguilar, Madhuri Wadehra & Lynn K. Gordon. (2019) Epithelial Membrane Protein-2 (EMP2) Antibody Blockade Reduces Corneal Neovascularization in an In Vivo Model. Investigative Opthalmology & Visual Science 60:1, pages 245.
Crossref
Sermsiri Sangroongruangsri, Usa Chaikledkaew, Suthasinee Kumluang, Olivia Wu, Claudia Geue, Tanapat Ratanapakorn, Pattara Leelahavarong, Lily Ingsrisawang, Paisan Ruamviboonsuk, Wongsiri Taweebanjongsin, Janejit Choovuthayakorn, Apichart Singalavanija, Prut Hanutsaha, Kittisak Kulvichit, Thitiporn Ratanapojnard, Warapat Wongsawad & Yot Teerawattananon. (2018) Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study. Clinical Drug Investigation 38:9, pages 853-865.
Crossref
M B McGuinness, R P Finger, A Karahalios, R H Guymer, D R English, E W Chong, A M Hodge, L D Robman, G G Giles & J A Simpson. (2017) Age-related macular degeneration and mortality: the Melbourne Collaborative Cohort Study. Eye 31:9, pages 1345-1357.
Crossref
Ian J. Constable, Chooi-May Lai, Aaron L. Magno, Martyn A. French, Samuel B. Barone, Steven D. Schwartz, Mark S. Blumenkranz, Mariapia A. Degli-Esposti & Elizabeth P. Rakoczy. (2017) Gene Therapy in Neovascular Age-related Macular Degeneration: Three-Year Follow-up of a Phase 1 Randomized Dose Escalation Trial. American Journal of Ophthalmology 177, pages 150-158.
Crossref
Robert S. Bresalier, H. Franklin Herlong & Boris Blechacz. 2016. Holland-Frei Cancer Medicine. Holland-Frei Cancer Medicine 1 16 .
Zuhair H. Peracha & Philip J. Rosenfeld. (2016) Anti–Vascular Endothelial Growth Factor Therapy in Pregnancy. Retina 36:8, pages 1413-1417.
Crossref
Pasquale F. Innominato & René Adam. (2016) Use of Bevacizumab in the Management of Potentially Resectable Colorectal Liver Metastases: Safety, Pathologic Assessment and Benefit. Current Colorectal Cancer Reports 12:4, pages 208-216.
Crossref
John W. Kitchens, Diana V. Do, David S. Boyer, Desmond Thompson, Andrea Gibson, Namrata Saroj, Robert Vitti, Alyson J. Berliner & Peter K. Kaiser. (2016) Comprehensive Review of Ocular and Systemic Safety Events with Intravitreal Aflibercept Injection in Randomized Controlled Trials. Ophthalmology 123:7, pages 1511-1520.
Crossref
Ivana Mikačić & Damir Bosnar. (2016) Intravitreal Bevacizumab and Cardiovascular Risk in Patients with Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies. Drug Safety 39:6, pages 517-541.
Crossref
Yin ZhangYunlong YangKayoko HosakaGuichun HuangJingwu ZangFang ChenYun ZhangNilesh J. SamaniYihai Cao. (2016) Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapy. Proceedings of the National Academy of Sciences 113:15, pages 4158-4163.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.